Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | June 03, 2026 | June 04, 2026 |
| Vericel CorpVCEL · Entity 4481 | Director · President and CEO | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2036-06-02 | Direct | 35,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,000 · Balance 35,000 F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Vericel Corp
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 303,020 |
Reported balance
After 2026-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 303,020 F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 321,270 |
Reported balance
After 2026-02-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 321,270 F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,446 |
Reported balance
After 2026-02-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-24 · Tax withholding · Disposed 8,824 · Balance 312,446 F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,500 |
Reported balance
After 2026-02-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 36,500 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 54,750 |
Reported balance
After 2026-02-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 54,750 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8: The Fair Market Value of the vested derivative securities is $38.09 per share. F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F7: No expiration date for this type of award. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7: No expiration date for this type of award.
F8: The Fair Market Value of the vested derivative securities is $38.09 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,548 | $48.47 | $75,031.56 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,647 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:13 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 35,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000545 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,750 Underlying: Common Stock · 35,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2022. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:13 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 1,945 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000545 · primary_01.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,945 Underlying: Common Stock · 1,945 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:13 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 298,055 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000545 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,055 Underlying: Common Stock · 298,055 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $49.23 | $369,225.00 |
DisclosureSEC source: 0001593968-21-000437 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,267 | $49.23 | $160,834.41 |
DisclosureSEC source: 0001593968-21-000437 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,195 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000437 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:24 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 6,938 | $47.18 | $327,334.84 |
DisclosureSEC source: 0001593968-21-000362 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,875 Underlying: Common Stock · 6,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:24 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,078 | $47.18 | $145,220.04 |
DisclosureSEC source: 0001593968-21-000362 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,962 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:24 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000362 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. Read SEC document |
| June 30, 2020 Filed Jan 28, 2021 21:23 UTC | Vericel Corp VCEL · Entity 4481 | GrantCommon Stock | 610 | $7.23 | $4,412.44 |
DisclosureSEC source: 0001593968-21-000239 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,102 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 21:58 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,684 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0000899243-20-018159 · doc4.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,684 Underlying: Common Stock · 23,684 shares Expires 2030-06-28 F1 · derivative.exercise_date: This option was granted on June 29, 2020. This option is scheduled to vest as to (i) 50% of the underlying shares on the earlier of (A) the first anniversary of the date of grant and (B) the date of the first annual meeting of stockholders of the Issuer held following the date of grant and (ii) the remaining 50% of the underlying shares on the earlier of (A) the second anniversary of the date of grant and (B) the date of the second annual meeting of stockholders of the Issuer held following the date of grant. Read SEC document |
| May 08, 2020 Filed May 8, 2020 20:09 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-20-001133 · primary_01.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 13,125 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. Read SEC document |
| May 08, 2020 Filed May 8, 2020 20:09 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 13,125 | $2.75 | $36,093.75 |
DisclosureSEC source: 0001593968-20-001133 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:26 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-20-000454 · primary_01.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 13,125 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:26 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 10,313 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001593968-20-000454 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,183 Underlying: Common Stock · 10,313 shares Expires 2026-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 165,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:26 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 13,125 | $2.75 | $36,093.75 |
DisclosureSEC source: 0001593968-20-000454 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:26 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,313 | $1.95 | $20,110.35 |
DisclosureSEC source: 0001593968-20-000454 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:08 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 5,555 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000437 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,555 Underlying: Common Stock · 5,555 shares Expires 2030-02-11 F1 · derivative.exercise_date: These options shall begin vesting on February 11, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:08 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000437 · primary_01.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 11, 2021. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:08 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 219,445 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000437 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,445 Underlying: Common Stock · 219,445 shares Expires 2030-02-11 F1 · derivative.exercise_date: These options shall begin vesting on February 11, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 22:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 6,937 | $17.28 | $119,871.36 |
DisclosureSEC source: 0001593968-20-000376 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,813 Underlying: Common Stock · 6,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2021, February 6, 2022, and February 6, 2023, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 22:03 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 3,179 | $17.28 | $54,933.12 |
DisclosureSEC source: 0001593968-20-000376 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,791 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 22:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000376 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2021, February 6, 2022, and February 6, 2023, respectively. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 16,250 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-19-001973 · primary_01.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 16,250 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 90,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 16,250 | $2.65 | $43,062.50 |
DisclosureSEC source: 0001593968-19-001973 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-19-001973 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 90,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:12 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 40,000 | $2.65 | $106,000.00 |
DisclosureSEC source: 0001593968-19-001973 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 58,125 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-19-001972 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,875 Underlying: Common Stock · 58,125 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:03 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 58,125 | $14.88 | $864,650.06 |
DisclosureSEC source: 0001593968-19-001972 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,783 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2019. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). F1 · ownership.direct: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 58,125 | $2.75 | $159,843.75 |
DisclosureSEC source: 0001593968-19-001972 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). F1 · ownership.direct: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 8,692 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001593968-19-000483 · primary_01.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,496 Underlying: Common Stock · 8,692 shares Expires 2026-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 165,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001593968-19-000483 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,452 Underlying: Common Stock · 27,500 shares Expires 2025-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 440,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 8,692 | $1.95 | $16,949.40 |
DisclosureSEC source: 0001593968-19-000483 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 27,500 | $3.02 | $83,050.00 |
DisclosureSEC source: 0001593968-19-000483 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 303,998 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001593968-19-000394 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,998 Underlying: Common Stock · 303,998 shares Expires 2029-02-06 F1 · derivative.exercise_date: These options shall begin vesting on February 6, 2019 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 27,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-19-000394 · primary_01.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with 6,937 RSUs vesting on February 6, 2020, 6,938 RSUs vesting on February 6, 2021, 6,937 RSUs vesting on February 6, 2022, and 6,938 RSUs vesting on February 6, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 6,002 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001593968-19-000394 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,002 Underlying: Common Stock · 6,002 shares Expires 2029-02-06 F1 · derivative.exercise_date: These options shall begin vesting on February 6, 2019 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 21:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-18-001418 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2017-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 21:02 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 50,000 | $15.39 | $769,500.00 |
DisclosureSEC source: 0001593968-18-001418 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,163 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 21:02 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 50,000 | $2.75 | $137,500.00 |
DisclosureSEC source: 0001593968-18-001418 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 20:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001593968-18-001323 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,188 Underlying: Common Stock · 75,000 shares Expires 2026-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 165,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 20:03 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 75,000 | $15.02 | $1,126,500.00 |
DisclosureSEC source: 0001593968-18-001323 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,163 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 20:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 75,000 | $1.95 | $146,250.00 |
DisclosureSEC source: 0001593968-18-001323 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 17,812 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · derivative · entry 11 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,188 Underlying: Common Stock · 17,812 shares Expires 2026-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date, February 9, 2016. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 1,548 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · derivative · entry 10 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,952 Underlying: Common Stock · 1,548 shares Expires 2025-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date, January 5, 2015 Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · derivative · entry 9 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date, February 8, 2017. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,826 | $14.00 | $39,564.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 8 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,559 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 3,083 | $14.00 | $43,162.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,385 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 2,077 | $14.00 | $29,078.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,468 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.